GLOW

What it is

GLOW combines BPC-157 (the healing pentadecapeptide), TB-500 (a thymosin-beta-4 fragment), and GHK-Cu (the blue copper peptide) into a single subcutaneous blend. The logic is straightforward and the reason the stack exists: BPC-157 and TB-500 handle deep-tissue repair and recovery, while GHK-Cu handles collagen, connective tissue, and skin. It’s marketed for recovery plus an aesthetic “glow,” and the street taxonomy is real — Bakri confirms “Wolverine” (BPC + TB-500) plus GHK-Cu is exactly the “glow stack” people have converged on.

Each component has its own full wiki page and evidence story. This page covers the rationale for running them together, what each brings, and the honest state of the science.

How it works

GLOW bundles three complementary mechanisms:

• BPC-157 drives angiogenesis (new blood-vessel growth) and works through the FAK–paxillin and nitric-oxide pathways to accelerate tissue repair; in one tendon model it increased growth-hormone receptor density on the tendon. Rodent work from the Sikiric group also documents BPC-157 interactions with the dopaminergic system (attenuating haloperidol-induced catalepsy and amphetamine-induced stereotypy) and the serotonergic system (region-specific changes in 5-HT synthesis in the rat brain) — single-lab evidence with no human replication yet, but mechanism-relevant for the “BPC reduces neurological stress load alongside tissue repair” framing that runs through the practitioner literature.
• TB-500 binds actin, the protein skeleton cells use to move, and promotes cell migration into wounds — which is precisely why it’s paired with BPC-157 for repair.
• GHK-Cu carries copper into fibroblasts and signals them to lay down collagen and elastin, regulating both synthesis and breakdown (remodeling). At the gene-expression level, a Broad Institute Connectivity Map analysis by Pickart and Margolina identified expression changes of ≥50% in 4,192 of 13,424 human genes assayed (~31%) after GHK exposure across the standard CMap human cell-line panel. Note that this is modulation (both up- and down-regulation), not pure activation, and the data source is mining of an existing public dataset rather than a wet-lab experiment — meaningful but worth framing precisely. Serum GHK itself drops with age: approximately 200 ng/mL at age 20 declining to approximately 80 ng/mL by age 60 — a roughly 60% reduction across four decades that tracks with measurable declines in regenerative capacity, collagen synthesis, and wound healing.

These slot together cleanly: BPC and TB do the structural repair, GHK-Cu does the skin and connective-tissue rebuild and the gene-expression reset. Dr. Jones makes the sharpest case for why this particular combination is coherent — GHK-Cu lives in two categories at once, longevity and repair, and that dual nature is, in his words, “why the GLOW stack actually works”. The component mechanisms are well-characterized individually; the combination rationale is the natural extension of putting a repair signal, a migration signal, and a collagen/remodeling signal in the same protocol.

What the research shows

Honest framing up front: there is no published study of the three-peptide combination itself — a PubMed search for BPC-157 + TB-500 + GHK-Cu returns zero records in any model [PubMed: 0 records]. That combination gap is real and is tracked in questions.md. What GLOW is built on is the component evidence, which is what every practitioner running it is actually relying on. By tier:

GHK-Cu: the best-evidenced component:

• Topical human cosmetic studies (40–71 women, 12 weeks) showing firmer, denser skin, reduced fine lines, improved elasticity; a comparative trial showed collagen deposition in 70% of users vs. 50% for vitamin C.
• Injectable form: consistent animal collagen/wound data (rats, dogs).
• The “28% collagen” figure is a McGill press release, not yet a peer-reviewed paper — treat as a reported finding.

BPC-157:

• Strong, consistent animal data for tendon, ligament, muscle, nerve, and gut healing; striking CNS-regeneration findings.
• Human data is thin: a 2024 systematic review of 544 screened articles found one clinical study (a 12-patient retrospective case series), plus older small Phase 1/2 ulcerative-colitis enema trials with no reported toxicity. No carcinogenic signal in animal data; in a melanoma model BPC actually decreased VEGF.

TB-500:

• Animal and in-vitro repair data. Human trials exist for pharmaceutical-grade thymosin beta-4 (full 43-aa protein and clinical eye drops) — promising in dry eye/neurotrophic keratopathy — but those used the clinical protein, not the 7-aa research fragment. A 2025 STEMI RCT of recombinant Tβ4 found no significant overall infarct-size reduction.

One place that reviews all three together: the 2026 Mendias musculoskeletal-peptide review covers BPC-157, TB-500, and GHK-Cu (alongside AOD-9604, CJC-1295, ipamorelin, MOTS-C, sermorelin, SS-31, tesamorelin) in a single safety-and-efficacy survey — a useful, current, one-stop reference for the components that make up GLOW [REVIEW preprint, Mendias 2026, DOI 10.20944/preprints202512.1011.v3]. It’s a preprint, so it’s a map of the component evidence, not new combination data — but it’s the closest thing to a single document that treats the whole stack’s ingredients at once.

On the repair base (BPC + TB-500), the real-world signal is strong even though the trial signal is thin. The BPC-157 + TB-500 pairing inside GLOW is the same “Wolverine” base that peptide clinics run as their default healing protocol, and the user-experience tier supplies the vivid anecdotes — e.g. a near-complete jiu-jitsu tricep tear back to training in ~3 months and a 2-decade chronic elbow tendonitis “almost completely gone” in 8 weeks. Tag these as n=1 experience, not efficacy data — but they’re the kind of repeated real-world result that explains why the base stack is so widely used. GHK-Cu adds the documented age-decline restoration angle (serum GHK-Cu falls ~60% from age 20 to 60), which is the mechanistic logic behind the “glow.”

Where it stands: the strongest single piece (topical GHK-Cu) has real human backing; the repair components are predominantly animal-grade for the injectable route, which is normal for bleeding-edge peptides. Clinic copy sometimes attaches quantified numbers to the blend — “200% faster healing,” “70% collagen improvement,” “fine lines in 2–3 weeks” — those are extrapolated or unsourced, not measured for the combination, so we don’t repeat them as combination facts. The defensible claim is the one the components support: a coherent repair-plus-skin stack whose individual signals are real, whose combination is plausible and widely used, and whose formal combination study is the field’s open gap.

Real-world protocol

The doses and schedules below are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

The de-facto convention for GLOW, stated plainly:

• Ratio: a roughly 5:1:1 GHK-Cu : TB-500 : BPC-157 blend is the common commercial pattern; one widely-cited clinic protocol lists BPC-157 5 mg / TB-500 10 mg / GHK-Cu 27–50 mg per vial. Alyve’s GLOW vial is a 70 mg total blend (COA shows GHK-Cu 49.64 mg of that).
• Reconstitution: total mg ÷ mL of BAC water = mg/mL; draw your target dose on a U-100 insulin syringe. A common approach is 2–3 mL BAC water in the vial, then a daily 10-unit draw, cycled 4–6 weeks on with time off. Refrigerate the reconstituted solution and use within ~14 days [Alyve handling copy].
• Trade-off vs. buying separately: GLOW fixes the ratio, so you can’t independently titrate each component the way you could with standalone BPC-157, TB-500, and GHK-Cu. That’s the cost of the convenience — and the benefit is one verified vial, one reconstitution, one injection.

Expert disagreement worth knowing. One practitioner is against putting GHK-Cu in the same vial as growth-factor peptides like BPC and TB-500, citing receptor competition and conflicting signals; his rule is GHK-Cu in the morning, other peptides hours later. Trigili joins this separation camp from a different angle — his argument is that the three peptides have meaningfully different half-lives and optimal frequencies (BPC short / daily and timed around training; TB-500 long / weekly after a two-week loading phase; GHK-Cu daily but on its own gene-expression timeline), so a fixed-ratio pre-made blend guarantees at least one of the three is always being administered wrong. The counter-position comes from people who compound these for a living: Kirkland says GLOW-type blends look clean on HPLC after years of formulating, and the real failure mode is a couple of specific incompatible pairs (retatrutide + NAD), not blends in general. Dr. Jones endorses GLOW directly. So: the single-vial objection has more than one practitioner-camp voice behind it, the rebuttal on chemistry stability is real, and the most honest framing is that both sides have a point — the blend wins on convenience and verified-ratio per-batch chemistry, separate vials win on per-compound dose-and-frequency control. Show both sides; the evidence and Rick decide.

A third voice with chemistry-grounded numbers — and the correction that comes with it (Holyfield, with verified counter-data). Josh Holyfield (a returning OHM-source practitioner with 14 prior digests in this KB) gave a quantitative intermediate position on the blend-vs-separate question on 2026-06-26: that blend efficacy loss is real but small (his estimate: ~5-10% averaged across GLOW over 30 days; ~10-15% on TB-500 specifically, attributed to methionine oxidation accelerated by GHK-Cu’s copper). His framing reduces the question to two real chemistry variables: amino-acid composition (oxidation-prone residues) and ionic compatibility (opposite charges aggregating). The framing is useful pedagogically; the specific methionine concern needs correction.

The verified chemistry, after a primary-source pass:

• Amino-acid composition / methionine oxidation: Holyfield’s claim that “TB-500 contains methionine, which makes it vulnerable to oxidation accelerated by GHK-Cu’s copper” applies to the full thymosin β4 (43-aa) protein (which has Met⁶, oxidation-prone) — but NOT to the actual TB-500 that vendors sell. The research-chem TB-500 in GLOW blends is the N-acetylated 7-amino-acid fragment Ac-LKKTETQ (residues 17-23 of Tβ4), confirmed by Wikipedia + multiple vendor monographs (Cayman Chemical, Delta Peptides, Peptide Biologix). Ac-LKKTETQ contains no methionine — only Leu, Lys, Thr, Glu, Gln. BPC-157 has no methionine. KPV has no methionine. So while the underlying copper-catalyzed methionine oxidation mechanism IS real chemistry [Stadtman ER, Free Radic Biol Med 1990;9(4):315-25; PMID 2283087], it has no substrate in a standard GLOW blend. Valor Sciences’ formulation analysis confirms this directly (https://valorsciences.com/2026/01/21/mix-ghk-cu-tb500-bpc157-stability/). The headline concern of GLOW degradation from Met oxidation does not apply to the actual product.
• Ionic compatibility / opposite-charge aggregation: the charge directionality holds — BPC-157 and TB-500 are net-negative at solution pH (BPC-157 pI ~3.6–5.1; Ac-LKKTETQ TB-500 pI ~4.6–5.1), GHK-Cu and KPV are net-positive (GHK-Cu basic from Lys + His side chains with no acidic residues; KPV pI ~8.14). But the leap from “opposite charges in the same vial” to “demonstrated aggregation that reduces functional concentration in a reconstituted-vial scenario” is not supported by published evidence at the dilute concentrations used in research-chem peptide blends. Self-assembly literature shows ordered/charged peptides at high concentrations can form complexes; short unstructured peptides at vial-realistic concentrations don’t have published demonstration of meaningful aggregation. Mechanism-plausible, empirically-undemonstrated.
• Practical resolution: even granting Holyfield’s full original 5-10% degradation framing as a worst case, most users finish a GLOW vial in 14-21 days at standard dosing — well inside the 30-day window where degradation is small even on his original chemistry. With the corrected chemistry above, the realized in-vial degradation is even smaller than Holyfield estimated. The trade-off for the user is a (very) small efficacy hit in exchange for one injection vs. three or four.

Where this leaves the debate: the one practitioner / Trigili anti-blend case rests on receptor competition + half-life mismatch + dose-frequency control concerns (real arguments that don’t depend on in-vial chemistry); the Kirkland / Jones blend-defense rests on HPLC stability + direct endorsement of GLOW use. The Holyfield-with-verified-correction position lands close to Kirkland/Jones on the chemistry — the in-vial degradation concerns that get repeated on social media largely don’t apply to the actual GLOW formulation. The honest takeaway: single-vial vs separate-vials is a real practical choice based on dose-control and convenience preferences, not a chemistry-degradation crisis.

Per-peptide cycle floors (practitioner-camp consolidated framing). Across the consensus the practitioner literature converges on these minimums:

• BPC-157: minimum 8 weeks, with compounding gut / brain-axis / tissue benefits typically becoming measurable around 12 weeks. A load-then-maintenance discipline (start at the low end of the 250-500 mcg/day range, assess body response in the first two weeks, then consider pushing toward the higher end) is the safer starting pattern.
• TB-500: loading phase weeks 1-2 (5 mg twice/week) → maintenance phase weeks 3-12 (5 mg once/week). Daily dosing is unnecessary given TB-500’s longer half-life and arguably counterproductive past receptor saturation.
• GHK-Cu: minimum 12 weeks to see the real ceiling on gene-expression-mediated collagen and connective-tissue remodeling. Cycles cut at 8 weeks stop right when the compounding effect is reportedly becoming measurable. Caveat: these timing windows come from practitioner observation, not from a published RCT pinning a “week 6-12 inflection” — the standard 12-week cosmetic-trial endpoint (Watson et al., Br J Dermatol 2009; Leyden 2002) is a trial-design convention, not a demonstrated efficacy curve. Treat the 6-12 / 8-12 week timing as practitioner-camp pattern, not as research-backed kinetics.

Common protocol mistakes

The pattern that recurs across practitioner critiques of how the GLOW stack actually gets run in the wild — useful as both a user-education checklist and a sanity-check before starting a cycle:

1. Wrong dosing — in both directions. Underdosing out of fear, or overdosing on the “more is better” reflex. Past receptor-saturation thresholds the additional drug is wasted, and some practitioners argue chronically aggressive doses risk receptor desensitization that erodes the long-term response. Different goals (injury recovery vs systemic anti-aging vs skin remodeling) call for different doses — most users never explicitly pick one.
2. Wrong timing for the half-life mismatch. BPC-157 is short-half-life and benefits from daily dosing timed around training; TB-500 is long-half-life and arguably counterproductive when forced into a daily schedule; GHK-Cu runs on its own gene-expression timeline. One frequency for all three guarantees at least one is mis-administered.
3. Same-vial, same-frequency execution. A pre-made blend locks both the ratio and the injection schedule. This is the heart of the one practitioner / Trigili separation argument covered in section 4. The Kirkland / Jones rebuttal on HPLC stability is real; the trade-off is convenience vs per-compound control.
4. Cutting the cycle too short. Stopping at four weeks because “nothing’s happening” is the single most common reason the stack reportedly under-delivers. GHK-Cu’s gene-expression-mediated effects, TB-500’s systemic repair, and BPC-157’s gut/brain-axis effects all compound over weeks, not days. Per the cycle-floor framing in section 4 — 8 weeks minimum for BPC, 12 weeks minimum for GHK-Cu — cutting at 4 weeks is reading a fraction of the curve.
5. Skipping the foundational supplementation. GHK-Cu’s collagen-synthesis pathway needs vitamin C and glycine as raw materials; copper-zinc balance interacts with how much of the GHK-Cu copper signal actually does its work; magnesium and omega-3s amplify the neurological and anti-inflammatory mechanisms BPC and TB-500 are driving. The peptides are the signal; the foundation is what lets the signal build something durable. Covered in detail in the next section.

The honest takeaway: GLOW under-delivers far more often from bad execution than from being the wrong stack for the user.

Foundational supplementation

Peptides do not work in isolation — every regenerative compound is acting on a substrate the body has to be able to provide. Per the peptides-KB scope expansion that explicitly covers supplements and adjuncts that materially affect peptide outcomes, the GLOW stack has a small, mechanism-tied foundation worth running alongside the injections. Standard nutrition-biochemistry; nothing exotic:

• Vitamin C, ~1-2 g/day. Prolyl hydroxylase and lysyl hydroxylase — the enzymes that crosslink collagen during synthesis — require vitamin C as a cofactor. GHK-Cu activates collagen-synthesis pathways; without adequate vitamin C the synthesis substrate is rate-limited regardless of the peptide signal. Most adults run chronically suboptimal on this without knowing.
• Glycine and/or collagen peptides, ~10 g/day. Glycine is roughly one-third of collagen by amino-acid composition (every third residue in the collagen triple-helix). Both BPC-157 and GHK-Cu are calling for accelerated structural building-block turnover; most adults under-consume glycine relative to that demand. Hydrolyzed collagen peptides or stand-alone glycine both work.
• Magnesium glycinate, 300-500 mg before bed. BPC-157 acts on the brain-gut axis and dampens neurological stress load (rodent mechanism noted in section 2); magnesium directly supports the same axis through NMDA modulation and GABA-system support. Glycinate is the well-tolerated bedtime form.
• Omega-3s (EPA/DHA), 2-4 g/day. TB-500 and BPC-157 drive anti-inflammatory mechanisms through one set of pathways; omega-3s drive specialized pro-resolving mediator (SPM) precursors and shift the AA-derived eicosanoid balance — a complementary anti-inflammatory route that compounds with what the peptides are doing.
• Zinc-copper balance (only if zinc is being supplemented). Zinc and copper compete for intestinal absorption — chronic zinc supplementation above ~60 mg/day for several weeks has been documented to reduce copper-status markers, and zinc induces enterocyte metallothionein which preferentially binds copper [PMID 3968585; NIH ODS Copper Fact Sheet]. The conservative rule: if you’re not supplementing zinc, this is not a concern; if you are, balance with copper (or accept the ratio risk) and don’t push past the 40 mg/day adult upper limit for zinc. Honest framing note: the broader practitioner claim that zinc supplementation specifically “undermines GHK-Cu therapy” is a reasonable inference but not directly documented — what’s documented is that zinc lowers copper absorption generically. For an OHM reader running GHK-Cu, the practical implication is the same (don’t supplement zinc unsupervised), but the wiki shouldn’t overclaim the GHK-Cu-specific mechanism.

The empowering framing: this foundation is cheap, well-established, and removes the most common reason people get less than the full benefit from regenerative peptides. The fear framing (some practitioners use this section as a “see, you need our coaching to do it right”) is not the OHM read — an informed reader can build the foundation themselves.

Side effects & management

No blend-level safety dataset exists, so this is assembled from the components and from user reports — all generally mild:

• Injection-site reactions — redness, swelling, occasional bruising, plus a copper-related sting from the GHK-Cu fraction — are the most common reports. Rotating sites and dosing with food (for GHK-Cu GI upset) are the standard mitigations.
• BPC-157: occasional mild fatigue or digestive change anecdotally; a theoretical VEGF/angiogenesis consideration (more tissue and vessels overlaps machinery a latent tumor could use) — no carcinogenic signal in animal data, but worth knowing.
• GHK-Cu copper load: avoid in Wilson’s disease and hemochromatosis; practitioner guides also flag pregnancy and under-18, and caution with active cancer.
• WADA: BPC-157 and TB-500 are prohibited for competitive athletes — relevant if you compete tested.

No serious adverse events surface in the indexable community reports for the stack, which is reassuring without being a formal safety profile. Cycling and staying in the conventional dose range is how users manage the unknowns.

Regulatory status

Not FDA-approved. None of the three components is approved for human injection; GHK-Cu is approved only as a topical cosmetic ingredient. Injectable GHK-Cu, BPC-157, and KPV were moved to the FDA’s restricted compounding category in 2023, with a review meeting scheduled for July 2026 [web, Scientific American]. BPC’s acetate form was reportedly removed from Category 2 in April 2026 but not yet placed on Category 1. Alyve sells GLOW research-use-only.

The Alyve product

• SKU: GLOW (BPC-157 / TB-500 / GHK-Cu), 70 mg blend — $118.00 on sale (regular $124). In stock. (ALYVE-GLOW-BLEND)
• Purity: third-party COA from Freedom Diagnostics Testing — 99.16% purity, identity-confirmed (GHK-Cu/TB-500/BPC-157) by LC-MS, lot GLO951.
• Why that matters: a blend is only as trustworthy as its components, and a three-peptide vial is exactly where gray-market quality problems compound: wrong peptide, off-ratio, TFA-salt contamination. This isn’t hypothetical: a 2026 Mendias-group preprint that purity-tested 6,441 gray-market peptide samples across 14 compounds (including BPC-157, GHK-Cu, and TB-500 — every GLOW component) is exactly the kind of market-wide data that quantifies the off-spec problem a COA solves [purity-testing preprint, Mendias group 2026]. Kirkland’s point that GLOW blends hold up on HPLC is reassuring in principle; a per-batch COA proves it for the specific vial in your hand. Alyve’s >99% identity-confirmed result is the verified-clean tier this category badly needs.
• Offer: use coupon OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. A 4–6 week cycle plus the recovery use-case makes the 3-bottle stack the natural commitment buy.

Sources

• PubMed: combination search = 0 records (0019 corpus: 4 review-only co-mentions, no primary combination study — the honest framing this page uses). Components — PMIDs 26236730, 18644225, 8227353, 8669775 (GHK-Cu); 40756949 (BPC-157 systematic review); 41229390 (Tβ4 STEMI RCT); 30063853 (Tβ4 eye-drop human data).

• Blend-stability chemistry additions (added 2026-06-26 via verified Holyfield-digest extension):

  • PMID 2283087 — Stadtman ER. “Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences.” Free Radic Biol Med. 1990;9(4):315-25. Canonical reference for the copper-catalyzed methionine oxidation mechanism (real chemistry, but moot for GLOW since vendor TB-500 has no Met).
  • Valor Sciences blend-stability myth-debunk — https://valorsciences.com/2026/01/21/mix-ghk-cu-tb500-bpc157-stability/. Direct counter-source confirming that the methionine-oxidation argument doesn’t apply to the Ac-LKKTETQ TB-500 fragment used in commercial blends.
  • TB-500 sequence reference — https://en.wikipedia.org/wiki/TB-500. Confirms Ac-LKKTETQ as the residues 17-23 fragment used in research-chem TB-500 (no methionine).
  • Tβ4 full-sequence reference — PNAS 1981; 78(2):1162-1166 (G-actin binding affinity studies that established Met⁶ oxidation sensitivity in the full protein, NOT in the synthetic fragment).
  • Peptide pI sources — BPC-157 pI ~3.6-5.1 (Biovera, Valor Sciences, precision.fda.gov); TB-500 (Ac-LKKTETQ) pI ~4.6-5.1 (Valor Sciences); KPV pI ~8.14 (Apex Laboratory, Peptpedia, Cayman Chemical).

• Mechanism additions (added 2026-06-26 via verified Trigili-digest extension):

  • PMID 29986520 — Pickart L, Margolina A. “Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.” Int J Mol Sci 2018;19(7):1987. DOI: 10.3390/ijms19071987. The 4,192-of-13,424-genes (~31%) Connectivity Map analysis.
  • PMC4508379 — Pickart L, Vasquez-Soltero JM, Margolina A. “GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.” BioMed Res Int 2015;2015:648108. The serum GHK age-decline data (200→80 ng/mL, age 20→60, ~60% reduction).
  • PMID 10499368 — Jelovac N, Sikiric P, et al. “Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics.” Eur J Pharmacol 1999;379(1):19-31. DOI: 10.1016/s0014-2999(99)00486-0. Rodent dopaminergic interaction.
  • PMID 15531385 — Tohyama Y, Sikirić P, Diksic M. “Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain.” Life Sci 2004;76(3):345-57. DOI: 10.1016/j.lfs.2004.08.010. Rodent serotonergic effects.
  • PMID 3968585 — Hoogenraad TU et al. “Copper and zinc absorption: mechanism of mutual antagonism.” Foundational mechanism citation for the zinc-copper interaction.
  • NIH ODS Copper Fact Sheet for Health Professionals — secondary anchor for the zinc-copper UL framing.

• Preprints (0019): Mendias 2026 musculoskeletal-peptide safety/efficacy review covering BPC-157/TB-500/GHK-Cu + 7 others, DOI 10.20944/preprints202512.1011.v3; Mendias-group 2026 gray-market peptide purity study (6,441 samples / 14 compounds incl. all three GLOW components).

• Web: Revolution Health GLOW blog; Jay Campbell / BioLongevity GLOW protocol; AH-Clinics; Nulevel Wellness; Scientific American “The Science Behind the Peptide Craze” (Apr 2026).

• Video: (Wolverine/glow taxonomy); (GLOW endorsement, dual-category GHK-Cu); (anti-blend argument); (HPLC stability rebuttal); (BPC+TB base case studies); (clinic-default combo); (GHK-Cu age-decline + 4-mechanism map); ** (added 2026-06-26 — five-mistakes framing, foundational supplementation stack, separation-camp voice, per-peptide cycle floors); (added 2026-06-26 — quantitative intermediate position on blend stability with verified correction: vendor TB-500 has no methionine, so the headline copper-catalyzed-Met-oxidation concern doesn’t apply to actual GLOW; ionic-aggregation theoretical-only at vial concentrations).**

Components: BPC-157 · TB-500 · GHK-Cu. Related blends: KLOW (GLOW + KPV).